Long-acting injectable antipsychotics: An expert opinion from the Association des médecins psychiatres du Québec;Les antipsychotiques injectables à action prolongée: Avis d'experts de l'Association des médecins psychiatres du Québec

Canadian Journal of Psychiatry

Volumn 56, Issue 6, 2011, Pages 367-376

  Stip, Emmanuel ^a,b   Abdel Baki, Amal ^a   Bloom, David ^c   Grignon, Sylvain ^d   Roy, Marc André ^e,f  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITÉ DE SHERBROOKE   (Canada)

^e UNIVERSITÉ LAVAL   (Canada)

^f CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LONG ACTING ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; CANADA; HUMAN; PRESCRIPTION;

EID: 79960439010     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371105600608     Document Type: Article

References (44)

1. Anonyme. Avis d'experts sur les APAP. Encéphale. 2009;3:85-124.
2. Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry. 2009;195:63-67.
3. Agarwal MR, Sharma VK, Kishore KV, et coll. Non-compliance with treatment in patients suffering from schizophrenia: a study to evaluate possible contributing factors. Int J Soc Psychiatr. 1998;44:92-106. (Pubitemid 28352140)
4. Rabinovich M, Béchard-Evans L, Schmitz N, et coll. Early predictors of nonadherence to antipsychotic therapy in first-episode psychosis. Can J Psychiatry. 2009;54(1):28-35.
5. Lepage M, Bodnar M, Buchy L, et coll. Early medication adherence and insight change in first-episode psychosis. Clin Schizophr Relat Psychoses. 2010;201-208.
6. Cassidy CM, Rabinovitch M, Schmitz N, et coll. A comparison study of multiple measures of adherence to antipsychotic medication in first-episode psychosis. J Clin Psychopharmacol. 2010;30(1):64-67.
7. Stip E, Guevremont C. Letter to editor: medication adherence and cost in schizophrenia: the Dopill® experiment. J Clin Psychiatry. Encore sous presse: 2011.
8. Guèvremont C, Sablier J, Stip E. DoPill, an electronic pill dispenser, helping control medication adherence in patients with schizophrenia. Schizophr Res. 2010;117:278.
9. Velligan D, Weiden PJ, Sajatovic M, et coll. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(4):1-46.
10. Llorca PM. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatr Res. 2008;161(2):235-247.
11. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002;106(4):286-290.
12. Misdrahi D, Llorca PM, Lançon C, et coll. Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications. Encéphale. 2002;28(3):266-272.
13. Lieberman JA, Koreen AR, Chakos M, et coll. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry. 1996;57(9):5.
14. Citrome L. Olanzapine pamoate: a stick in time, a review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int J Clin Pract. 2009;63(1):140-150.
15. Lewis SW, Tarrier N, Drake RJ. Integrating non-drug treatments in early schizophrenia. Br J Psychiatry. 2005;48:65-71.
16. Chue P, Eederkens M, Augustyns I, et coll. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005;15(1):111-117.
17. Adams CE, Fenton MK, Quraishi S, et coll. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry. 2001;179:290-299. (Pubitemid 32996037)
18. Lieberman JA, Stroup S, McEnvoy JP, et coll. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223. (Pubitemid 41345943)
19. Quraishi S, David A. Depot haloperidol decanoate for schizophrenia. Cochrane Database Syst Rev. 2000;2:CD001361.
20. Hosalli P, Davis JM. Depot risperidone for schizophrenia. Cochrane Database Syst Rev. 2003;4:CD004161.
21. David A, Adams CE, Eisenbruch M, et coll. Depot fluphenazine decanoate and enanthate for schizophrenia. Cochrane Database Syst Rev. 2005;1:CD000307.
22. Lauriello J, Lambert T, Andersen S, et coll. An 8-week, doubleblind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry. 2008;69(5):790-799. (Pubitemid 351838688)
23. Dinesh M, David A, Quraishi SN. Depot pipotiazine palmitate and undecylenate for schizophrenia. Cochrane Database Syst Rev. 2004;4:CD001720.
24. Leucht C, Heres S, Kane JM, et coll. Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1-3):83-92.
25. Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry. 2003;16:14-17. (Pubitemid 37523323)
26. Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic clinical studies. J Clin Psychiatry. 2003;64(16):34-40. (Pubitemid 37523326)
27. Marois MJ, Roy MA. Haloperidol decanoate doses of 200, 100, or 50 mg/month reduced symptomatic exacerbations more than a 25 mg/month dose in schizophrenia. Am J Psychiatry. 2002;159(4):554-560.
28. Coutinho E, Fenton M, Quraishi SN. Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses. Cochrane Database Syst Rev. 2000;2:CD001164.
29. Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychological Med. 2003;33(1):83-89. (Pubitemid 36113403)
30. Patel MX, De Zoysa N, Baker D, et coll. Antipsychotic depot medication and attitudes of community psychiatric nurses. J Psychiatr Ment Health Nurs. 2005;12(2):237-244. (Pubitemid 40515360)
31. Shi L, Ascher-Svanum H, Ahu B, et coll. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv. 2007;58:482-488.
32. NHS. Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. NICE clinical guideline 2009 [Internet]. London (GB): NICE: 2009 [dernier accès le 2011 avr 4]. Disponible à l'adresse : http://www.nice.org.uk/CG82.
33. Williams R, Kopala L, Malla A, et coll. Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia. Acta Psychiatr Scand Suppl. 2006;430:12-21.
34. Kreyenbuhl J, Buchanan RW, Dickerson FB, et coll. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36(1):94-103.
35. Edwards NC, Rupnow MFT, Pashos CL, et coll. Cost-effectiveness model of long-acting risperidone in schizophrenia in the United States. PharmacoEconomics. 2005;23(3):299-314.
36. Llorca PM, Miadi-Fargier H, Lançon C, et coll. Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation. Encéphale. 2005;31(2):235-246.
37. Byerly M, Fisher R, Whatley K, et coll. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatr Res. 2005;133:129-133.
38. Weiden P, Glazer W. Assessment and treatment selection for "revolving door" inpatients with schizophrenia. Psychiatr Q. 1997;68(4):377-392.
39. Harrison G, Hopper K, Craig T, et coll. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry. 2001;178:506-517. (Pubitemid 32531743)
40. Marshall M, Bond GR, Huxley P. Vocational rehabilitation for people with severe mental illness. Cochrane Database Syst Rev. 2008;3:CD003080.
41. Twamley EW, Jeste DV, Lehman AF. Vocational rehabilitation in schizophrenia and other psychotic disorders: a literature review and meta-analysis of randomized controlled trials. J Nerv Ment Dis. 2003;191(8):515-523. (Pubitemid 37071720)
42. Heres S, Schmitz FS, Leucht S, et coll. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol. 2007;22(5):275-282.
43. Walburn J, Gray R, Gournay K, et coll. Systemic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry. 2001;179:300-307. (Pubitemid 32996038)
44. Rosenheck RA, Krystal JH, Lew R, et coll. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364(9):842-851.